|HUM-MOLGEN -> Events -> Meetings and Conferences|
|HUMAN PROTEOME PROJECT|
|December 06, 2000|
Cambridge Healthtech Institute, McLean, Virginia
April 2-4, 2001
Without doubt the Human Genome Project has taken several giant steps into the twenty-first century, both for science and for self-knowledge. As its fruits fall into our hands, it is important to acknowledge the remarkable efforts and insights that made this happen. We should also note that despite this outstanding success, many new questions have concomitantly emerged. Beneath this new gestalt, we now face a more complicated view of ourselves. Logically, on this incremental path to self-advancement, we now confront the Proteome. Our main goal is to actuate public and private energies to fuse into a single panoply. Consensual and careful planning at the outset will harness the naturally occurring forces of politics and markets, technology and pure research. Underscoring the sine qua non status of cooperation, round-table discussions are planned in plenary session. These will be moderated by respected independent figures. The politics of inclusion will be front and center at all times.
|Organized by:||Cambridge Healthtech Institute|
|Invited Speakers:||Dr. Stanley Abramowitz, National Institute of Standards and Technology
Dr. Norman G. Anderson, Large Scale Biology Corporation
Dr. Paul Bardel, Myriad Genetics, Inc.
Dr. Franklin Berger, JP Morgan Securities Inc.
Dr. Allan Bombard, Aetna U.S. Healthcare
Dr. Marvin Cassman, National Institute of General Medical Science
Dr. Julio Celis, Danish Centre for Human Genome Research
Dr. Jasemine Chambers, U.S. Patent and Trademark Office
Dr. Christopher Earl, Perseus LLC
Dr. Christine Ethier, Genomic Solutions, Inc.
Dr. James I. Garrels, Proteome, Inc.
Dr. John Hefti, Signature BioScience, Inc.
Dr. Ian Humphery-Smith, University of Utrecht and Glaucus Proteomics B.V.
Dr. Trey Ideker, The Institute for Systems Biology
Dr. Stephen Kingsmore, Molecular Staging
Dr. Joshua LaBaer, Harvard Medical School
Dr. Lance Liotta, National Cancer Institute
Dr. Matthias Mann, Protana A/S
Dr. Ralph McDade, Luminex Corporation
Dr. Michael P. McKenna, CuraGen Corporation
Dr. Raj Parekh, Oxford GlycoSciences
Dr. Ari Patrinos, U.S. Department of Energy
Dr. Dale Patterson, Perceptive Biosystems, Inc.
Dr. Emanuel Petricoin III, U.S. Food and Drug Administration
Mr. Antonio Regalado, Wall Street Journal
Dr. Monica Riley, Woods Hole Oceanographic Institute
Dr. Peter Roepstorff, Odense University
Dr. Ajay Royyuru, T. J. Watson IBM Research Center
Dr. Richard D. Smith, Pacific Northwest National Laboratory
Dr. Subramanyam Swaminathan, Brookhaven National Laboratory
Mr. John E. Tarcza, Large Scale Proteomics Corporation
Dr. Brad Walsh, Macquarie University
Dr. John Wiktorowicz, Lynx Therapeutics, Inc.
|Deadline for Abstracts:||March 2, 2001|
|Posted by:||Jennifer Laakso|